European Journal of Cancer and Clinical Oncology最新文献_第6页

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results 干扰素α -2b联合VMCP与单独VMCP的诱导效果比较，干扰素α -2b与对照组的缓解维持效果比较:中期结果

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90570-4

Heinz Ludwig , Amos M. Cohen , Heinz Huber , David Nachbaur , Walter F. Jungi , Hansjörg Senn , Peter Günczler , Johannes Schüller , Sándor Eckhardt , Heinz L. Seewann , Franco Cavalli , Elke Fritz , Michael Micksche

{"title":"Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results","authors":"Heinz Ludwig , Amos M. Cohen , Heinz Huber , David Nachbaur , Walter F. Jungi , Hansjörg Senn , Peter Günczler , Johannes Schüller , Sándor Eckhardt , Heinz L. Seewann , Franco Cavalli , Elke Fritz , Michael Micksche","doi":"10.1016/0277-5379(91)90570-4","DOIUrl":"10.1016/0277-5379(91)90570-4","url":null,"abstract":"<div><p>The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance treatment improve treatment results in patients with multiple myeloma. Up to now 89 patients have received IFN plus vincristine/melphalan/cyclophosphamide/prednisolone (VMCP) as induction therapy, and 86 conventional VMCP. The proportion of patients with progressive disease was significantly lower (<em>P</em> < 0.005) under IFN + VMCP as compared to the VMCP treatment group. Survival times were significantly longer (<em>P</em> < 0.02) after IFN + VMCP induction therapy than after VMCP alone. In the second phase of this investigation, 33 progression-free myeloma patients were assigned to receive IFN as maintenance therapy, and 41 patients served as untreated controls. Patients maintained with IFN showed a tendency towards increased progression-free survival. Haematological side effects were observed significantly more often in patients receiving IFN, with more severe haematological toxicity in patients on the combined IFN + VMCP regimen and an increased number of patients with mild haematological toxicity in the group maintained with IFN. Other side effects, such as fever and fatigue, remained within tolerable limits. In conclusion, the preliminary results of this current clinical trial indicate significant advantages of combined IFN + VMCP induction treatment in terms of reduced disease progression and prolonged survival and possible benefits of IFN maintenance therapy in patients with multiple myeloma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90570-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Carmustine-induced toxicity, DNA crosslinking and 06-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines 卡莫司汀对两种人肺癌细胞系的毒性、DNA交联和06-甲基鸟嘌呤-DNA甲基转移酶活性

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90440-O

Suzanne Egyházi , Jonas Bergh , Johan Hansson , Peter Karran , Ulrik Ringborg

{"title":"Carmustine-induced toxicity, DNA crosslinking and 06-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines","authors":"Suzanne Egyházi , Jonas Bergh , Johan Hansson , Peter Karran , Ulrik Ringborg","doi":"10.1016/0277-5379(91)90440-O","DOIUrl":"10.1016/0277-5379(91)90440-O","url":null,"abstract":"<div><p>O<sup>6</sup>-methylguanine-DNA methyltransferase (O<sup>6</sup>-MT) probably plays an important role in the repair of chloroethyl-nitrosourea-induced DNA damage. O<sup>6</sup>-MT was studied as a possible drug resistance factor in two human lung cancer cell lines, one small cell lung cancer (U1690) and one non-small cell lung cancer (U1810), with different sensitivities to carmustine. The U1810 cell line was 3.4-fold more resistant to carmustine than U1690 cells, although the two cell lines were equally sensitive to mustine, melphalan and cisplatin. A 23-fold higher level of DNA interstrand crosslinks was observed following exposure of U1690 cells to carmustine compared with U1810 cells. The O<sup>6</sup>-MT activity of U1810 cells was 11 times higher than that of U1690 cells. The O<sup>6</sup>-MT activity in the U1810 cells showed a dose-dependent decrease after exposure to carmustine. These results show a correlation between increased O<sup>6</sup>-MT activity, decreased drug induced DNA interstrand crosslinking and cellular resistance to carmustine.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90440-O","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon 在持续静脉输注白细胞介素-2与干扰素时添加白蛋白的重要性

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90432-D

James Cassidy, Christopher Poole, Elizabeth Sharkie, Will P. Steward, Stanley B. Kaye

引用次数: 5

Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means? 老年小细胞肺癌化疗的回顾性回顾:目的是否可以证明手段的合理性?

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90422-A

M.P.N. Findlay, A.-M. Griffin, D. Raghavan, K.E. McDonald, A.S. Coates, P.J. Duval, P. Gianoutsos

{"title":"Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means?","authors":"M.P.N. Findlay, A.-M. Griffin, D. Raghavan, K.E. McDonald, A.S. Coates, P.J. Duval, P. Gianoutsos","doi":"10.1016/0277-5379(91)90422-A","DOIUrl":"10.1016/0277-5379(91)90422-A","url":null,"abstract":"<div><p>Between 1978 and 1983, 72 patients aged 70 years or older (median 72, range 70–80) were treated for biopsy-proven, small cell lung cancer (SCLC). Intercurrent disorders were common, including ischaemic heart disease, peripheral vascular disease, chronic airflow limitation and second malignancies. 26 patients (36%) had limited extent of disease, and 46 (64%) had extensive disease. “Intensive” chemotherapy incorporating vincristine, cyclophosphamide and doxorubicin (OCA regimen) was administered to 32 patients [complete response (CR) + partial response (PR) = 84%]; less rigorous regimens (e.g. single agent chemotherapy, planned dose reductions, radiotherapy only) were used in 34 cases (CR + PR = 52%); and 6 received no active treatment. In the intensively treated group, there were 3 treatment-related deaths and 26 episodes of WHO grade 3–4 toxicity. In the less intensively treated group, there were no treatment-induced deaths and only 1 episode of severe toxicity. The overall median survival was 25 weeks (36 weeks for intensive treatment, 16 weeks with less intense treatment). For patients with limited disease only, the median survival in each group was 43 and 26 weeks, respectively. Intensive treatment for elderly patients with small cell lung cancer is associated with substantially increased toxicity and higher response rates than for gentle treatment, but without a major survival benefit.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90422-A","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 73

Cancer registration and incidence in Hawaii 夏威夷的癌症登记和发病率

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90450-R

Marc T. Goodman , Grant N. Stemmermann

引用次数: 1

Increased levels of soluble interleukin-2 receptors in supernatants from peripheral blood mononuclear cells of patients with lung cancer 肺癌患者外周血单个核细胞上清液中可溶性白细胞介素-2受体水平升高

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90455-M

Pietro Marino , Armando Preatoni , Gianfranco Buccheri , Domenico Ferrigno , Adriana Fruttero

引用次数: 0

In vitro methods for screening agents with an indirect mechanism of antitumour activity: Xanthenone analogues of flavone acetic acid 体外筛选具有间接抗肿瘤作用机制的药物的方法:黄酮乙酸的杂蒽酮类似物

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90446-K

Lai-Ming Ching, Graeme J. Finlay, Wayne R. Joseph, Bruce C. Baguley

引用次数: 13

Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis α干扰素治疗原发性血小板增多症和其他骨髓增生性疾病伴血小板增多症

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90578-2

Xenophon Yataganas, John Meletis, Eleni Plata, Nora Viniou, Filippos Deligiannis, Christina Tsekoura, Ersi Voscaridou, Viki Boussiotis, John Rombos, Georges Vayopoulos, Christos Kittas, Phaedon Fessas

{"title":"Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis","authors":"Xenophon Yataganas, John Meletis, Eleni Plata, Nora Viniou, Filippos Deligiannis, Christina Tsekoura, Ersi Voscaridou, Viki Boussiotis, John Rombos, Georges Vayopoulos, Christos Kittas, Phaedon Fessas","doi":"10.1016/0277-5379(91)90578-2","DOIUrl":"10.1016/0277-5379(91)90578-2","url":null,"abstract":"<div><p>The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 × 10<sup>9</sup>/L was achieved in 94%, and below 400 × 10<sup>9</sup>/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90578-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Alpha interferon in the management of essential thrombocythaemia α干扰素在原发性血小板血症治疗中的应用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90579-3

Manuel Giralt , Daniel Rubio , Ma Teresa Cortés , Jesús San Miguel , Juan Luis Steegmann , Jesús Serena , Jose Ma Fernández-Rañada , Antonio López-Borrasca

{"title":"Alpha interferon in the management of essential thrombocythaemia","authors":"Manuel Giralt , Daniel Rubio , Ma Teresa Cortés , Jesús San Miguel , Juan Luis Steegmann , Jesús Serena , Jose Ma Fernández-Rañada , Antonio López-Borrasca","doi":"10.1016/0277-5379(91)90579-3","DOIUrl":"10.1016/0277-5379(91)90579-3","url":null,"abstract":"<div><p>Thirteen patients (mean age 60.7 years; female:male ratio 10:3) with essential thrombocythaemia were treated with 3 million units (MU)/day interferon alfa-2b subcutaneously (s.c.) for 12 weeks, with all patients requiring a dose reduction after 4 weeks. The mean pretreatment platelet count was 1,400 × 10<sup>9</sup>/L and megakaryocytes were increased in all cases. Splenomegaly was present in six patients and haemorrhagic phenomena were observed in two. Nine patients (69.2%) had objective responses, including two (15.4%) complete responses (platelets < 450 × 10<sup>9</sup>/L) which were then maintained with 5 MU interferon twice a week. Acute toxicity consisted of flu-like symptoms in 12 patients. Chronic toxicity (mainly leucopenia) was observed in nine patients. In conclusion, alpha interferon is a useful agent for the treatment of essential thrombocythaemia, reducing platelet count after initial therapy and then requiring maintenance therapy at a reduced dose. However, the frequent side effects observed make it advisable to use a low dose of interferon alfa-2b, and to treat only those patients with significant symptoms and signs of thrombocytosis.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90579-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Infusion of floxuridine plus etoposide plus cisplatin in human malignancies 氟尿定+依托泊苷+顺铂输注治疗恶性肿瘤

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90421-9

J. Lokich, C. Moore, N. Anderson, M. Bern

{"title":"Infusion of floxuridine plus etoposide plus cisplatin in human malignancies","authors":"J. Lokich, C. Moore, N. Anderson, M. Bern","doi":"10.1016/0277-5379(91)90421-9","DOIUrl":"10.1016/0277-5379(91)90421-9","url":null,"abstract":"<div><p>36 patients with advanced malignancy were studied in a phase I trial of continuous 24-h infusion of floxuridine (FUdR) plus etoposide plus cisplatin (FEP) administered for 5 consecutive days at 4-week intervals. Study design fixed the dose rate of etoposide and cisplatin with escalation of FUdR only. Dose rate-limiting toxicity related to the FUdR component was stomatitis and diarrhoea and was invariably associated with leukopenia and thrombocytopenia when grade 3 or 4 level gastrointestinal toxicity was observed. Only 3 of 64 courses were associated with transient renal failure related to cisplatin. Drug-related deaths occurred (leukopenia-associated sepsis) in 4 patients with poor performance status (ECOG 3 and 4). Responses occurred in 15 of 26 evaluable patients (all previously treated minimally or untreated) including <span><math><mtext>5</mtext><mtext>11</mtext></math></span> non-small cell lung cancer; <span><math><mtext>3</mtext><mtext>3</mtext></math></span> oesophageal; <span><math><mtext>2</mtext><mtext>2</mtext></math></span> breast; <span><math><mtext>4</mtext><mtext>5</mtext></math></span> gastric; 1 osteogenic sarcoma; and 1 unknown primary (probably ovary). The recommended dose rates for a 5-day infusion of the three agents for good risk patients is 20 mg/m<sup>2</sup> per day of each drug. For poor risk patients including age > 65 years; performance status 2 or greater; or extensive bone metastases or prior radiation; the recommended starting dose rates are: FUdR 15 mg/m<sup>2</sup> per day; etoposide 15 mg/m<sup>2</sup> per day; and cisplatin 20 mg/m<sup>2</sup> per day. Dose escalation of FUdR to a maximum of 25 mg/m<sup>2</sup> daily is feasible in selected patients demonstrating optimal tolerance.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90421-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12998575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3